Author:
de Heer Pieter,Sandel Maro H.,Guertens Gunther,de Boeck Gert,Koudijs Margaretha M.,Nagelkerke J. Fred,Junggeburt Jan M. C.,de Bruijn Ernst A.,van de Velde Cornelis J. H.,Kuppen Peter J. K.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference49 articles.
1. Labianca R, Beretta G, Gatta G, de Braud F, Wils J (2004) Colon cancer. Crit Rev Oncol Hematol 51:145–170
2. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596
3. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142
4. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62:2029–2033
5. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献